Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Allowed claims are expected to cover novel methylone-inspired neuroplastogenic compounds for potential treatment of post-traumatic stress disorder (PTSD) and other psychiatric disorders CAMBRIDGE, Mass. — Enveric Bioscie
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.